Related Experiment Video
Updated: Nov 13, 2025
TMT Sample Preparation for Proteomics Facility Submission and Subsequent Data Analysis
Published on: June 8, 2020
Data Management of Sensitive Human Proteomics Data: Current Practices, Recommendations, and Perspectives for the
Nuno Bandeira1, Eric W Deutsch2, Oliver Kohlbacher3
1Center for Computational Mass Spectrometry, University of California, San Diego (UCSD), La Jolla, California, USA; Department Computer Science and Engineering, University of California, San Diego (UCSD), La Jolla, California, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego (UCSD), La Jolla, California, USA.
Managing sensitive human proteomics data is crucial. Balancing data privacy with open access is essential for scientific advancement and preventing reputational damage in the proteomics field.
Area of Science:
- Proteomics
- Bioinformatics
- Data Privacy
Background:
- Public proteomics data repositories are standard for scientific publications.
- Clinical proteomics studies are increasing, raising concerns about sensitive human data management and dissemination.
- Existing legal frameworks in the US and EU protect individual privacy.
Purpose of the Study:
- To address the emerging challenges in managing and disseminating clinical proteomics data.
- To highlight the need for proactive measures by the proteomics community.
- To balance data privacy with the benefits of open access for research reuse.
Main Methods:
- Review of current practices in proteomics data sharing.
- Analysis of privacy risks associated with human proteomics data.
- Examination of legal and ethical frameworks for data management.
- Consideration of controlled access models used in genomics and transcriptomics.
Main Results:
- Increased clinical proteomics necessitates robust privacy management.
- Failure to address identifiability risks can damage the field's reputation.
- Barriers to open access can hinder biomedical research discoveries.
- A careful balance between privacy and data sharing is required.
Conclusions:
- The proteomics community must proactively manage privacy risks in clinical data.
- Development is needed in bioinformatics infrastructure, policymaking, and oversight mechanisms.
- Striking a balance is key to enabling data reuse and advancing biomedical research.
